Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study-Reference-Cited by-同舟云学术

Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study

Published:2004-03 Issue:3 Volume:15 Page:504-510
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Belhadj K.,Delfau-Larue M.-H.,Elgnaoui T.,Beaujean F.,Beaumont J.-L.,Pautas C.,Gaillard I.,Kirova Y.,Allain A.,Gaulard P.,Farcet J.-P.,Reyes F.,Haioun C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/15/3/504/557709/mdh090.pdf

Reference36 articles.

1. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma;Bierman;J Clin Oncol,1997

2. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma;Khouri;J Clin Oncol,1998

3. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma;Gianni;N Engl J Med,1997

4. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group;Santini;J Clin Oncol,1998

5. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study;Haioun;J Clin Oncol,2000

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients;Cytotherapy;2023-12

2. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04);International Journal of Hematology;2016-03-21

3. Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation;Journal of Hematopoietic Cell Transplantation;2016

4. Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation;Current Opinion in Hematology;2015-11

5. Stem cell transplantation in follicular lymphoma;Clinical Guide to Transplantation in Lymphoma;2015-05-15